Long acting ß2-agonists and glucocorticoids together control asthma in ~95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting ß2-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising. It can decrease the exacerbation rates in severe COPD and may also decrease mortality.

Interactions between long-acting ß2-agonists and glucocorticoids

CARAMORI, Gaetano;PAPI, Alberto;
2006

Abstract

Long acting ß2-agonists and glucocorticoids together control asthma in ~95% of affected individuals, although symptoms return after treatment is stopped. Treatment of chronic obstructive pulmonary disease (COPD) scarcely influences the natural course of the disease. Neither long-acting ß2-agonists (LABAs) nor glucocorticoids alone significantly influence the course of COPD. Recent evidence suggests that a combination of the two therapies is more promising. It can decrease the exacerbation rates in severe COPD and may also decrease mortality.
2006
Caramori, Gaetano; Ito, K.; Papi, Alberto; Adcock, I. M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11392/526168
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 7
  • ???jsp.display-item.citation.isi??? ND
social impact